<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Self-monitoring of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (SMBG) has been considered one major breakthrough in <z:mp ids='MP_0002055'>diabetes</z:mp> therapy because, for the first time, patients were able to determine their blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels during daily life </plain></SENT>
<SENT sid="1" pm="."><plain>It seems obvious that this must be of advantage to disease management and clinical outcome, but it has become a nightmare for those trying to provide evidence </plain></SENT>
<SENT sid="2" pm="."><plain>Randomised controlled trials have yielded inconsistent results on a benefit of SMBG-based treatment strategies not only in type 2 but - surprisingly - also in type 1 and <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Despite this, SMBG is being considered indispensible in intensive insulin treatment, but is being debated for other clinical settings </plain></SENT>
<SENT sid="4" pm="."><plain>When considering the non-RCT based reasons for recommending SMBG in type 1 and <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> it becomes apparent that the same reasons also apply to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>